Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Infectious Disease Partnering Head Patrick Schleck Describes Priorities
Executive Summary
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major biopharma industry developments, as reported by Scrip's global team.